Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ-154 foam in scalp and body psoriasis
NCT04128007Phase 2Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing ARQ-154 foam 0.3% with Vehicle foam (2 arms). Primary endpoint: Scalp Investigator Global Assessment Success at Week 8. Started Jan 2020; status: completed.
02
Drugs
roflumilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04128007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128007.